Insulin is one of the most important drugs in the history of pharmaceuticals. Since the separation of active insulin from animals by the Canadian doctor Frederick Grant Banting, it has been around for nearly a hundred years and has been continuously upgraded to meet the demand for diabetes. To… Continue Reading After OI388GT terminated the trial, Novo Nordisk deployed oral insulin again, and plans to enter the human clinical clinic within three years.

  What role will technology play in the healthcare industry in 2019? For venture capitalists and others interested in the medical industry, it is critical to be able to predict the direction of industry innovation more accurately than others. Recently, MedCity News has predicted five major innovation trends affecting the… Continue Reading These 5 major innovation trends will affect the medical and health industry in 2019.

  In 2006, Stanford University professor Andrew Z. Fire and University of Massachusetts Medical Professor Craigc. Mello won the 2006 Nobel Prize in Physiology/Medical for discovering RNA interference (RNAi) and their outstanding contributions in the field of gene silencing. At the time of the award, they predicted that the application… Continue Reading 2018 Top Ten RNA Therapy Company, the first place is not Moderna?

  EvaluatePharma recently released the “EP Vantage 2019 Preview” report, which uses the net present value method (NPV) to evaluate the market potential of new drugs in the world. Regarding the net present value, you can simply understand “how much is the value of a new drug asset at a… Continue Reading Outlook 2019: The world’s most valuable new drug TOP20

  In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.

  Biopharma Dive, a biopharmaceutical website, recently selected the annual pharmaceutical company (Mersha East), the annual biotechnology company (Spark Therapeutics), the annual CEO (Emma Walmsley, GSK), the annual transaction (Takeda $62 billion acquisition of Shire), the annual innovation (RNA Targeted therapy), an annual new drug (Ajin/Nuohua migraine drug Aimovig).  … Continue Reading BioPharma: Six “most” in 2018

  Cellular therapies based on effector T cells over the past decade, particularly CAR-T therapy, have revolutionized the treatment of many types of cancer. In 2017, the FDA approved two CAR-T therapies for the treatment of certain types of cancer associated with B cells, and research in the field of… Continue Reading How to apply CAR-T therapy to treat autoimmune diseases?

  The future of rindopepimut seems to be bright in 2015. The results of three clinical trials have shown that this peptide tumor therapeutic vaccine can elicit an immune response and delay polymorphic glioblastoma multiforme (GBM). The disease progression of the patient. GBM is the most malignant brain cancer. The… Continue Reading Bronze Age of Glioblastoma Immunotherapy

  In 2010, with the support of the international drug purchasing agency UNITAID, the Medicines Patent Pool (MPP) was established in Geneva. MPP negotiates with the original pharmaceutical company on the voluntary license of the drug patent. The original drug company puts its drug patent into the patent pool, and… Continue Reading Medicines Patent Pool: chicken ribs or opportunities?

  T cells have always been at the center of tumor immunotherapy. In recent years, CAR-T therapy has shown its power to treat certain types of cancer, and the FDA has approved two CAR-T therapies for the treatment of lymphoma or leukemia. At the same time, there are currently hundreds… Continue Reading How will CAR-NK therapy affect the progress of cell therapy?